Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • Entinostat (MS-275): Applied Workflows for Cancer Cell Inhib

    2026-06-05

    Entinostat (MS-275): Protocol-Driven Advances in Cancer Cell Proliferation Inhibition

    Principle Overview: Entinostat’s Mechanism and Experimental Foundations

    Entinostat (also known as MS-275 or SNDX-275) is a highly selective, orally available inhibitor of histone deacetylases (HDACs), targeting class I HDACs such as HDAC1 and HDAC3. Its potent inhibitory activity (IC50: 0.368 μM for HDAC1, 0.501 μM for HDAC3) makes it an essential tool for dissecting epigenetic control mechanisms in cancer biology. By blocking HDAC enzymatic activity, Entinostat increases histone acetylation, thereby relaxing chromatin structure and reactivating tumor suppressor genes or apoptotic pathways. This foundational mechanism underpins its strong anti-proliferative and pro-apoptotic effects in a broad spectrum of cancer cell lines, including breast, colon, lung, myeloma, ovary, pancreas, prostate, and leukemia, as detailed in the product information.

    Step-by-Step Workflow: Optimized Use of Entinostat in In Vitro Cancer Assays

    Implementing Entinostat in laboratory protocols requires attention to solubility, storage, and precise dosing to ensure consistent results. The following workflow integrates best practices from published methodologies and the latest advances in in vitro drug response assessment:

    Protocol Parameters

    • Stock Solution Preparation: Dissolve Entinostat in DMSO to a final concentration of 10 mM. Aliquot and store at ≤ –20°C. Thaw only once to avoid degradation.
    • Working Concentrations for Cell Treatment: Typical assay concentrations range from 0.1 μM to 5 μM. For robust cancer cell proliferation inhibition, begin with 1 μM and perform a serial dilution (e.g., 0.1, 0.5, 1, 2, 5 μM).
    • Treatment Duration: Incubate cells with Entinostat for 24–72 hours, adjusting duration based on cell line sensitivity and assay endpoint (cell viability or apoptosis induction).

    Assessments may utilize MTT/XTT viability assays, Annexin V/PI staining for apoptosis quantification, or western blotting to monitor histone H3/H4 acetylation. For water-insoluble compounds like Entinostat, ensure DMSO concentration in culture medium remains below 0.1% to minimize vehicle toxicity.

    Key Innovation from the Reference Study

    The doctoral dissertation IN VITRO METHODS TO BETTER EVALUATE DRUG RESPONSES IN CANCER introduces a crucial distinction between relative viability (reflecting both proliferation arrest and cell death) and fractional viability (measuring direct cell killing) in anti-cancer drug evaluation. This nuanced approach reveals that compounds like Entinostat may exert dual effects—simultaneously inhibiting proliferation and inducing apoptosis, with varying relative timing depending on cell context.

    For practical assay design, this means researchers should pair multiple readouts (e.g., real-time proliferation tracking and endpoint apoptosis assays) rather than relying solely on a single viability metric. This dual-metric strategy increases data fidelity and can reveal subtle differences in drug mechanism or timing, especially when optimizing dosage or comparing combination regimens.

    Advanced Applications and Comparative Advantages

    Entinostat’s value extends far beyond basic cytotoxicity screening. Its selective inhibition of HDAC1 and HDAC3 makes it particularly effective in models where epigenetic silencing of tumor suppressor genes drives malignancy. For example, in preclinical studies of Entinostat (MS-275, SNDX-275) in retinoblastoma, significant tumor burden reduction and increased histone acetylation were observed in vivo. This supports its use in retinoblastoma treatment research as well as broader solid tumor models.

    In the clinical translational arena, phase I trials have assessed Entinostat’s combination with agents like 13-cis retinoic acid for advanced solid tumors, establishing dose safety and paving the way for ongoing solid tumor clinical trials. These studies highlight Entinostat’s tolerability and synergistic potential with differentiation-inducing agents.

    Comparative benchmarks—such as those discussed in the article Scenario-Driven Solutions with Entinostat (MS-275, SNDX-275)—demonstrate its reliability in both cell-based and xenograft models, particularly when paired with epigenetic or cytotoxic co-treatments. This resource complements the workflow guidance here by offering scenario-based troubleshooting for maximizing assay reproducibility. For further comparison of HDAC1/3 inhibitors in translational oncology, see the atomic, mechanism-centric analysis in Entinostat (MS-275, SNDX-275): HDAC1/3 Inhibition for Precision Oncology Workflows.

    Troubleshooting and Optimization Tips

    • Solubility Solutions: If precipitation occurs during dilution, pre-warm DMSO and vortex thoroughly before further dilution into media. Use ultrasonic treatment when dissolving in ethanol (≥7.4 mg/mL).
    • Control for Vehicle Effects: Always include DMSO-only controls at the highest concentration used in treatment wells to rule out solvent-induced cytotoxicity.
    • Assay Timing: Monitor both early (24 h) and late (48–72 h) endpoints to capture the temporal dynamics of proliferation arrest versus apoptosis induction in cancer cells, as recommended in the reference study.
    • Batch Consistency: Use aliquoted stock solutions and avoid repeated freeze-thaw cycles, as Entinostat is sensitive to degradation above –20°C.
    • Multi-Parameter Readouts: Combine cell viability, apoptosis, and histone acetylation assays to distinguish between direct cytotoxicity and epigenetic reprogramming effects.

    Future Outlook: Toward More Informative Cancer Drug Assays

    As underscored by Schwartz’s in vitro investigation, integrating dual-metric approaches into drug screening—measuring both proliferation arrest and specific cell death—promises more predictive, mechanism-resolved insights into candidates like Entinostat. This paradigm not only refines our understanding of apoptosis induction in cancer cells but also supports rational combination strategies, such as pairing HDAC inhibitors with immune modulators or differentiation agents.

    Looking forward, Entinostat’s continued use in solid tumor clinical trials and preclinical retinoblastoma models will further clarify optimal dosing, safety windows, and synergistic regimens. As workflows mature, expect to see expanded adoption of standardized, multiparameter assay panels that reflect the reference study’s methodological recommendations—ultimately accelerating translation from bench to bedside.

    Why This Matters: Translational Impact and APExBIO’s Role

    Entinostat (MS-275, SNDX-275) exemplifies the power of targeted epigenetic modulation for cancer research. By following protocol-driven, evidence-backed workflows, investigators can unlock reproducible and actionable insights into proliferation inhibition and apoptosis induction across diverse cancer types. As a trusted supplier, APExBIO ensures batch-to-batch consistency and reagent quality critical for high-impact oncology research.